This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
The objectives of the review are to estimate the benefits and harms of:
-
azathioprine (AZA) compared with placebo or other disease -modifying treatments (DMTs) as first-choice treatment for relapsing forms of multiple sclerosis (MS);
-
AZA compared with placebo or other DMTs for relapsing forms of MS when switching from another DMT;
-
AZA compared with placebo or other DMTs as first-choice treatment for progressive forms of MS; and
-
AZA compared with placebo or other DMTs for progressive forms of MS when switching from another DMT.
This is a protocol.